biography ∙ philosophy ∙ education ∙ companies ∙ patents ∙ publications

Biography

Josh Shachar has been involved in advanced technologies for the Department of Defense for over 20 years. Josh has held many executive management positions at high-technology companies dealing directly with the United States Department of Defense. Josh began his professional career in 1981 at ThermoControl, Inc. in Chatsworth, California, as the founder and Vice President of Engineering. This company was acquired by Daily Instrument of Houston, Texas. In 1996, Josh served as the Vice President of Engineering at Pastushin Aviation, Inc. In the following year, Josh founded and served as the President of Lambda Signatics, Inc. which has been acquired by Shapco Industries. Josh is still the principal owner and founder of numerous other high-technology companies. These companies are ThermoCouple America LLC, EDEL Engineering Development Corp., and Engineered Magnetics, Inc. Descriptions of these companies are available upon request. Josh’s extensive academic background includes an MA from USC and a BA/MA in Science and Mathematics from the University of Haifa where he graduated Magna Cum Laude. In 1980, Josh received a Fulbright Scholarship. Josh has filed numerous U.S.

Patent applications in the Medical/Biometrics and Diagnostics areas. Between 1998 and 2000, Josh and his technical team, began their research to develop a local, non-systemic way to treat and cure solid tumor cancers.

Renowned oncologists acted as consultants, including some with up to 30 years experience in oncology with major pharmaceutical companies like Bristol-Myers Squibb.

Their research led them to the critical area of BRMs and Pleiotropic phenomenon, MTD and OBD in the context of cytotoxic drugs and their immunological effect. From their research it was learned that BRMs (such as different Interferon and Interleukins or IL-2in) in combination can improve solid malignant tumor elimination. However, due to the nature of BRMs that are both cytotoxic and Pleiotropic, it is extremely critical that highly controlled, accurate, optimal doses be administered to the cancer patient in order to avoid cytotoxic effects. Therefore, it seemed imperative to try to develop a local delivery system capable of accurately measuring and administering the optimum dose while monitoring the state of the tumor. In June 2002, Josh filed his patent entitled, “Method and Apparatus for Piezoelectric Layer-Wise Pump and Value for Use in Local Administration of Biological Response Modifiers and Therapeutic Agents”. At the core of Josh’s invention lies the notion of an implantable medical device. More particularly this device will be an improved operating system architecture incorporating a piezoelectric layer-wise pump and valve to administer BRMs and chemotherapeutic agents locally in solid malignant tumor fighting. The underlying implication in the use of cytotoxic drugs was that higher doses had a greater effect on the solid malignant tumor. Therefore, it was necessary to determine the MTD. However, when used in traditional treatment modes, such as intravenously or orally administered Chemo, the cytotoxic agents are delivered to the patient in a manner that allows the cytotoxic agents to be distributed more or less systemically throughout the entire body of the patient. Relatively large doses of the drugs are required since only a small fraction of the administered dose will be present at the solid malignant tumor site at any given time. The remainder of the dose will be in other parts of the body. Moreover, a major problem with conventional Chemo is the lack of specificity to the cancer cells. The use of large doses of toxic agents often leads to serious and debilitating side effects. Furthermore, the global administration of drugs is often not compatible with combination therapies where a number of medicating agents are used synergistically to treat solid malignant tumors or other conditions. Thus, the systemic administration of medicating agents to treat solid malignant tumors and other such medical conditions is an inefficient, often dangerous, technique that frequently leads to severe or debilitating side effects, severe degradation of the patient’s immune system and, in some cases, death.